Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tiumeq

- PMLiVE

BMS can ride on Sovaldi’s success as Daklinza cleared in EU

Hepatitis C drug approved in combination with Gilead’s huge-selling treatment

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

FDA approves Gilead drug in three blood cancers

Zydelig recommended for use in chronic lymphocytic leukaemia and two forms of lymphoma

- PMLiVE

Merck & Co taps music industry for US HIV campaign

Pharma company to work with music promoter Maria Davis and Positive Women’s Network – USA

- PMLiVE

Celgene’s cancer drug promising in small HIV study

Lymphoma therapy Istodax shows potential in treating the virus

- PMLiVE

Failed HIV cure can’t dent spirit at Melbourne conference

Still 'feasible' to end Aids epidemic by 2030

- PMLiVE

Pharma joins tributes to Aids researchers lost on flight MH17

Toll of Malaysian Airlines jet crash in Ukraine includes 'HIV hero' Dr Joep Lange

- PMLiVE

US senators seeks answers on Sovaldi pricing

Gilead asked to justify pricing of hepatitis drug

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links